- PR Newswire•5 hours ago
SAN DIEGO, Feb. 28, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of circulating tumor DNA (ctDNA) molecular diagnostics, is scheduled to attend the 29th Annual ROTH Conference, March ...
- Accesswire•27 days ago
LOS ANGELES, CA / ACCESSWIRE / February 1, 2017 / LD Micro is pleased to announce that the LD Micro Index is being reconstituted as of February 1, 2017. We believe that the existence of a true microcap ...
- PR Newswire•last monthPublication of Trovera™ KRAS Liquid Biopsy Test Demonstrates Clinical Utility in Advanced Cancers for Detection and Measurement of Therapeutic Response
SAN DIEGO, Jan. 24, 2017 /PRNewswire/ -- Trovagene, Inc. (TROV), a developer of circulating tumor DNA (ctDNA) molecular diagnostics, today announced the publication of study results in Clinical Cancer Research, demonstrating the analytical and clinical performance of Trovera™ urine and blood liquid biopsy tests to quantitatively assess KRAS mutations in patients with diverse advanced cancers. This data was also featured as a presentation at the 2017 Gastrointestinal Cancers Symposium on January 21st in San Francisco, CA. The data demonstrate the clinical utility of Trovagene's proprietary mutation-enrichment technology to detect and quantitate KRAS mutations in urine and plasma from patients with advanced cancers. This was a blinded study with prospectively collected liquid biopsy samples, and archived tissue samples with known KRAS mutation status, from 71 patients with diverse advanced cancers.
TROV : Summary for TrovaGene, Inc. - Yahoo Finance
TrovaGene, Inc. (TROV)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Bid||1.95 x 22300|
|Ask||2.00 x 3500|
|Day's Range||1.95 - 2.03|
|52 Week Range||1.78 - 6.93|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-1.52|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|